VivoSim Labs (VIVS)
Market Price (3/30/2026): $1.47 | Market Cap: $3.8 MilSector: Health Care | Industry: Biotechnology
VivoSim Labs (VIVS)
Market Price (3/30/2026): $1.47Market Cap: $3.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -88% | Weak multi-year price returns2Y Excs Rtn is -35%, 3Y Excs Rtn is -75% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8066% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -45% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -40% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 217% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7482%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7482% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% | ||
| High stock price volatilityVol 12M is 127% | ||
| Key risksVIVS key risks include [1] substantial financial distress and operational losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -88% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -45% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -35%, 3Y Excs Rtn is -75% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8066% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -40% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 217% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -7482%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7482% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% |
| High stock price volatilityVol 12M is 127% |
| Key risksVIVS key risks include [1] substantial financial distress and operational losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
VivoSim Labs (VIVS) stock has lost about 30% since 11/30/2025 because of the following key factors:
1. VivoSim Labs has reported significant and ongoing financial losses and negative profitability.
For the trailing twelve months ending December 31, 2025, the company recorded a net loss of -$1.2 million. As of March 19, 2026, diluted earnings per share stood at -$1.70, with operating income at -$12.6 million, reflecting an -8761.1% operating margin, and a net profit margin of -1727.8%. These figures underscore substantial unprofitability and a considerable cash burn.
2. Shareholders have experienced substantial dilution due to an increase in outstanding shares.
In the past year, the total shares outstanding for VivoSim Labs grew by 53.2%, with another source indicating an 84.51% increase over one year. This significant expansion in the share count has diluted the value of existing shares.
Show more
1. VivoSim Labs has reported significant and ongoing financial losses and negative profitability.
For the trailing twelve months ending December 31, 2025, the company recorded a net loss of -$1.2 million. As of March 19, 2026, diluted earnings per share stood at -$1.70, with operating income at -$12.6 million, reflecting an -8761.1% operating margin, and a net profit margin of -1727.8%. These figures underscore substantial unprofitability and a considerable cash burn.
2. Shareholders have experienced substantial dilution due to an increase in outstanding shares.
In the past year, the total shares outstanding for VivoSim Labs grew by 53.2%, with another source indicating an 84.51% increase over one year. This significant expansion in the share count has diluted the value of existing shares.
Show more
Stock Movement Drivers
Fundamental Drivers
The -27.7% change in VIVS stock from 11/30/2025 to 3/29/2026 was primarily driven by a -28.6% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.24 | 1.62 | -27.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 1.4% |
| P/S Multiple | 41.7 | 29.8 | -28.6% |
| Shares Outstanding (Mil) | 3 | 3 | -0.1% |
| Cumulative Contribution | -27.7% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| VIVS | -27.7% | |
| Market (SPY) | -5.3% | -4.3% |
| Sector (XLV) | -8.7% | 2.7% |
Fundamental Drivers
The -33.6% change in VIVS stock from 8/31/2025 to 3/29/2026 was primarily driven by a -30.8% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.44 | 1.62 | -33.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 43.0 | 29.8 | -30.8% |
| Shares Outstanding (Mil) | 3 | 3 | -4.0% |
| Cumulative Contribution | -33.6% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| VIVS | -33.6% | |
| Market (SPY) | 0.6% | 1.3% |
| Sector (XLV) | 5.2% | 3.4% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| VIVS | ||
| Market (SPY) | 9.8% | 2.9% |
| Sector (XLV) | -2.1% | 9.3% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| VIVS | ||
| Market (SPY) | 69.4% | 2.9% |
| Sector (XLV) | 18.4% | 9.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VIVS Return | - | - | - | - | -3% | -7% | -10% |
| Peers Return | -35% | -44% | 25% | -43% | 1% | -21% | -79% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| VIVS Win Rate | - | - | - | - | 44% | 33% | |
| Peers Win Rate | 36% | 37% | 52% | 33% | 55% | 13% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| VIVS Max Drawdown | - | - | - | - | -25% | -10% | |
| Peers Max Drawdown | -44% | -53% | -27% | -48% | -38% | -28% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SLP, CERT, SDGR, RXRX, RLAY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
VIVS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to SLP, CERT, SDGR, RXRX, RLAY
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About VivoSim Labs (VIVS)
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for VivoSim Labs (VIVS):
- A 3D Systems for human tissues and organs.
- Like a more advanced Charles River Labs, using human bioprinted tissues for drug testing.
- A Moderna for bioprinted human organ therapies.
AI Analysis | Feedback
nullAI Analysis | Feedback
VivoSim Labs (VIVS), which, according to the provided background, operates as Organovo Holdings, Inc., sells primarily to other companies.
Its major customers are companies involved in drug discovery and development. These typically include:
- Pharmaceutical companies
- Other biotechnology companies
These customers utilize VivoSim Labs' (Organovo Holdings, Inc.'s) ExVive human liver tissue and ExVive human kidney tissue for predictive preclinical testing of drug compounds.
AI Analysis | Feedback
nullAI Analysis | Feedback
Management Team
Norman Staskey, President and Chief Financial Officer
Mr. Staskey was appointed as President, Chief Financial Officer, and Principal Financial Officer of Organovo Holdings, Inc. (now VivoSim Labs, Inc.) in late 2024/early 2025. He brings over 25 years of experience in capital markets and mergers and acquisitions (M&A) transactions. Prior to his current role, Staskey served as a Managing Director at EY (formerly Ernst & Young), where he led or advised on several Fortune 500 M&A deals, including the merger of Dell Inc. and EMC Corporation. He has also served as Chief Financial Officer for various biotechnology companies, including Azitra, Inc. since October 2022, and as a Senior Director at Danforth Advisors, LLC since May 2021.
Keith Murphy, Executive Chairman
Mr. Murphy is the founder of Organovo Inc. (which rebranded as VivoSim Labs, Inc.) in 2007 and served as its CEO, leading all company operations until 2017. He is recognized for co-inventing the NovoGen MMX bioprinter platform and for growing the company through initial investments and corporate partnerships. Before founding Organovo, Mr. Murphy spent a decade at Amgen, where he held increasingly responsible positions, including four years as the Global Operations Leader of denosumab. He is currently the CEO and Chairman of Viscient Bio, Inc.
Curtis Tyree, Senior Vice President, Strategy and Business Development
Dr. Tyree is responsible for corporate partnerships, acquisitions, and R&D strategy at VivoSim Labs. His career includes senior positions at HUYABIO, where he played a role in developing the immunomodulator HIYASTA™ through its approval in Japan. He also contributed to the presentation of the first gamma secretase modulators for Alzheimer's Disease at TorreyPines Therapeutics and helped discover the thrombopoietin mimic Promacta® at Ligand Pharmaceuticals. Dr. Tyree holds a BSc in Microbiology & Immunology from McGill University and a PhD in Biology from UC San Diego.
AI Analysis | Feedback
The key risks for VivoSim Labs (VIVS) are:
- Clinical Development and Regulatory Approval Risk: VivoSim Labs is actively developing "in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases." This involves a complex, lengthy, and expensive process of clinical trials to demonstrate safety and efficacy, followed by rigorous regulatory approvals from health authorities. Any failures in clinical trials, significant delays, or inability to secure regulatory approval for these therapeutic products would pose a substantial risk to the company's future revenue and viability.
- Intellectual Property Protection Risk: The company's operations are underpinned by its "proprietary NovoGen Bioprinters" and "related technologies for preparing bio-inks and bioprinting multicellular tissues." The risk of competitors developing similar technologies, patent challenges, or the expiration of key patents could diminish VivoSim Labs' competitive advantage and market position.
- Market Adoption and Commercialization Risk: VivoSim Labs offers "ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds," and is also working on therapeutic in vivo tissues. The successful commercialization of these innovative 3D tissue models and future therapeutic products depends on their widespread adoption by pharmaceutical companies for drug testing and, for therapeutic applications, acceptance by the medical community and favorable reimbursement, which can be challenging for novel technologies.
AI Analysis | Feedback
nullAI Analysis | Feedback
VivoSim Labs (VIVS), formerly Organovo Holdings, Inc., focuses on developing 3D tissues for preclinical testing and in vivo liver tissues for therapeutic applications.
The addressable markets for VivoSim Labs' main products and services are as follows:
3D Human Tissue Models for Predictive Preclinical Testing (ExVive human liver tissue and ExVive human kidney tissue)
- The global human organoids market, which includes products for drug discovery and toxicology testing, was estimated at USD 804.0 million in 2024 and is projected to reach USD 2,715.6 million by 2030, growing at a compound annual growth rate (CAGR) of 22.8% from 2025 to 2030. Within this market, the "organoid models" segment held a 51.21% share in 2024. The liver segment dominated the human organoids market by organ type, representing a 23.34% revenue share in 2024. Another report projects the global organoids market to reach US$ 7.6 billion by 2033.
- The global 3D bioprinted human tissue market, covering research-based applications like drug discovery and toxicology testing, was estimated at USD 2.09 billion in 2025 and is projected to reach USD 5.78 billion by 2034, growing at a CAGR of 12.04%. The "drug discovery & toxicology testing" application segment dominated with a 41% share in 2025. Specifically, the liver tissue segment within this market is anticipated to register the fastest CAGR of 13.24%.
- The global human liver model market, used for toxicology testing and drug discovery, was valued at USD 1.34 billion in 2024 and is projected to grow at a CAGR of 14.04% from 2025 to 2030. This market is estimated to reach USD 6.69 billion by 2035.
In Vivo Liver Tissues for Therapeutic Applications (to treat end-stage liver, life-threatening, and orphan diseases)
- The global regenerative medicine market, a broader category for therapeutic tissues, was valued at USD 51.65 billion in 2025 and is projected to grow to USD 555.58 billion by 2034, exhibiting a CAGR of 31.27%. The U.S. regenerative medicine market size is evaluated at USD 15.86 billion in 2024 and is projected to be worth around USD 75.03 billion by 2034.
- The global liver disease therapeutics market was valued at USD 26.54 billion in 2025 and is projected to reach approximately USD 45.25 billion by 2035, expanding at a CAGR of 5.48% between 2026 and 2035. Another report indicates the global market for liver disease treatment was valued at $46.0 billion in 2024 and is projected to reach $69.1 billion by the end of 2030, at a CAGR of 7.1%.
- The liver cirrhosis market in the 7 Major Markets (7MM), which includes the U.S., Japan, Germany, France, Italy, Spain, and the U.K., was nearly USD 3,100 million in 2023. The U.S. alone accounted for approximately USD 2,180 million of this market in 2023.
AI Analysis | Feedback
For VivoSim Labs (symbol: VIVS), the following are expected drivers of future revenue growth over the next 2-3 years:
- Expansion into Asia-Pacific Markets: VivoSim Labs recently expanded its commercial presence in the Asia-Pacific region by signing distribution agreements in January 2026 with JCBio in South Korea and Tekon Biotech in China for its NAMKind™ human-based liver and small-intestine toxicology services. This strategic market expansion aims to capitalize on the growing in-vitro toxicology market in China, which is projected to reach $2.26 billion by 2030.
- Increased Adoption of New Approach Methodologies (NAMs): A significant driver is the anticipated accelerated adoption of human tissue models following the U.S. Food and Drug Administration's (FDA) announcement on April 10, 2025, to refine animal testing requirements in favor of non-animal NAM methods. This regulatory shift is expected to increase demand for VivoSim's NAMkind™ services, which offer more informative, faster, and more cost-effective solutions for drug testing, potentially reducing drug development costs and accelerating the delivery of safer treatments.
- Development and Commercialization of New NAMkind™ Models for Novel Drug Classes: VivoSim Labs is actively expanding the application of its NAMkind™ models. The company plans to present validation data in March 2026 for its liver and intestine models against marketed Antibody Drug Conjugates (ADCs), representing a "major new market" for their services. These models are designed to identify off-target toxicities in ADCs, thereby improving the selection of promising candidates for drug development.
- Strategic Partnerships and Collaborations: Beyond the recently announced distribution agreements, VivoSim Labs continues to explore and leverage strategic partnerships. The company's strategy involves seeking collaborations, potentially with pharmaceutical giants, to mitigate financial challenges, open new revenue streams, and advance its 3D bioprinting capabilities.
AI Analysis | Feedback
Share Issuance
- Organovo Holdings, Inc. completed a 1-for-12 reverse stock split on March 20, 2025, to regain compliance with Nasdaq's minimum bid price requirement, reducing outstanding shares from approximately 21.4 million to about 1.8 million.
- VivoSim Labs, Inc. reported approximately $1.8 million in "at-the-market equity proceeds" for the nine months ended December 31, 2025, indicating capital raised through share issuance.
- Shareholders have experienced substantial dilution over the past year.
Inbound Investments
- In March 2025, Organovo Holdings, Inc. sold its FXR program, including lead asset FXR314, to Eli Lilly and Company for an upfront payment of $10 million (or $9 million upfront with an extra $1 million after 15 months), with potential future milestone payments of up to $50 million.
Capital Expenditures
- Capital expenditures for Organovo Holdings Inc. were approximately $42,000 in 2024, $396,000 in 2023, and $409,000 in 2022.
- VivoSim Labs Inc. invested $13 in capital expenditures in Q4 2026.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Would You Still Hold VivoSim Labs Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VIVS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.67 |
| Mkt Cap | 0.9 |
| Rev LTM | 76 |
| Op Inc LTM | -89 |
| FCF LTM | 1 |
| FCF 3Y Avg | -57 |
| CFO LTM | 2 |
| CFO 3Y Avg | -53 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 19.8% |
| Rev Chg 3Y Avg | 13.4% |
| Rev Chg Q | 3.3% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | -469.0% |
| Op Mgn 3Y Avg | -456.3% |
| QoQ Delta Op Mgn LTM | 314.6% |
| CFO/Rev LTM | -247.6% |
| CFO/Rev 3Y Avg | -317.4% |
| FCF/Rev LTM | -253.7% |
| FCF/Rev 3Y Avg | -330.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 11.9 |
| P/EBIT | -2.9 |
| P/E | -4.8 |
| P/CFO | 4.6 |
| Total Yield | -22.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -5.5% |
| D/E | 0.1 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -13.5% |
| 3M Rtn | -33.1% |
| 6M Rtn | -40.2% |
| 12M Rtn | -43.2% |
| 3Y Rtn | -55.1% |
| 1M Excs Rtn | -6.5% |
| 3M Excs Rtn | -26.2% |
| 6M Excs Rtn | -35.6% |
| 12M Excs Rtn | -56.3% |
| 3Y Excs Rtn | -119.4% |
Price Behavior
Price Behavior
| Market Price | $1.62 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/14/2012 | |
| Distance from 52W High | -66.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.75 | $1.74 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -7.2% | -7.2% |
| 3M | 1YR | |
| Volatility | 174.0% | 127.2% |
| Downside Capture | -0.56 | 0.59 |
| Upside Capture | -262.39 | 63.08 |
| Correlation (SPY) | -7.4% |
VIVS Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -5.44 | -3.60 | -2.27 | -0.34 | 0.40 | -0.67 |
| Up Beta | -4.11 | -4.85 | -4.77 | -1.86 | -0.27 | -0.39 |
| Down Beta | 5.06 | 0.90 | 0.07 | 0.75 | 0.71 | 0.60 |
| Up Capture | -557% | -315% | -173% | -19% | 18% | 2% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 17 | 25 | 52 | 95 | 95 |
| Down Capture | -1278% | -761% | -259% | 10% | 21% | 13% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 22 | 33 | 67 | 110 | 110 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VIVS | |
|---|---|---|---|---|
| VIVS | -25.2% | 126.5% | 0.27 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 10.2% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 3.8% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -20.1% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -17.5% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 8.7% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 3.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VIVS | |
|---|---|---|---|---|
| VIVS | -5.6% | 126.5% | 0.27 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 10.2% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 3.8% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -20.1% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -17.5% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 8.7% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 3.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VIVS | |
|---|---|---|---|---|
| VIVS | -2.9% | 126.5% | 0.27 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 10.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 3.8% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -20.1% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -17.5% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 8.7% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 3.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/11/2026 | 10-Q |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 06/05/2025 | 10-K |
| 12/31/2024 | 02/19/2025 | 10-Q |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/31/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 07/14/2023 | 10-K |
| 12/31/2022 | 02/09/2023 | 10-Q |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 06/10/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gobel, David | Direct | Sell | 11192025 | 2.24 | 3,266 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.